Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis

Figure 3 Correlation between neuron-glial antigen 2 expression and clinicopathological features. A: Neuron-glial antigen 2 (NG2) expression in human hepatic carcinoma tissues at different clinical stages (a: TNM stage I; b: TNM stageII; c: TNM stage III; d: TNM stage IV); B: NG2 protein expression in human hepatic carcinoma tissues with different degrees of differentiation (a: Normally differentiated; b: Well differentiated; c: Moderately differentiated; d: Poorly differentiated); C: NG2 expression in human hepatic carcinoma tissues with portal vein invasion [a, c: Vascular invasion (magnification × 100); b, d: Vascular invasion (magnification × 400)]; D: NG2 expression in vessels within human hepatic carcinoma tissue [a, c: Tumor vessel (magnification × 200); b, d: Tumor vessel (magnification × 400)].